Company / Return on Assets (ROA)
Enliven Therapeutics, Inc. Return on Assets (ROA) History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-27.3%
FY2024
5-year range
-54.9% / -26.3%
FY2020-FY2024
Trend
-3.8%
vs FY2023
Sector context
#122 of 213
Health Care
What the data says
At -27.3%, Enliven Therapeutics, Inc.'s return on assets (roa) ranks #122 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 6 years, ranging from -70.5% in FY2019 to -26.3% in FY2023.
Based on SEC 10-K filings.
-27.3% in FY2024 with a 5-year CAGR of +43.1%.
Improved from -45.2% to -27.3% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +27.5pp
- 5-Year Change
- +43.1pp
- 10-Year Change
- -
Sector benchmark
#122 of 213 in Health CareTop 57% of 213This company -27.3% Sector average -24.2%
▼
-13.1% below sector average
Key checks
Key Insights
- In FY2024, return on assets (roa) decreased 3.8% year-over-year.
- Currently 3.2pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2023.
- Lowest return on assets (roa) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -27.3% | -3.8% |
| FY2023 | -26.3% | +41.8% |
| FY2022 | -45.2% | +17.6% |
| FY2021 | -54.9% | -20.5% |
| FY2020 | -45.5% | +35.4% |
| FY2019 | -70.5% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026